Back to top

A Phase I study that evaluated whether a gel containing dapivirine is safe for use in the rectum. The study, which enrolled 28 HIV-negative cisgender and transgender men and women at sites in Thailand and the U.S., will help determine whether further testing on the safety and acceptability of dapivirine gel as a potential rectal microbicide can be conducted in a larger population.

Bottoms Are Up at the HIV Research for Prevention Virtual Conference
2-February-2021

MTN-026 Backgrounder
30-October-2017

MTN-026 Q&A
30-October-2017

See Also
MTN-026 Protocol

MTN-026 Study Page

Rectal Microbicides - Fact Sheet
21-Apr-2020